var data={"title":"Mupirocin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Mupirocin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6610?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=mupirocin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Mupirocin: Patient drug information&quot;</a> and <a href=\"topic.htm?path=mupirocin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Mupirocin: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198518\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Bactroban;</li>\n      <li>Bactroban Nasal;</li>\n      <li>Centany;</li>\n      <li>Centany AT</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198519\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Bactroban</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198557\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Topical</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198521\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Impetigo: </b> Topical: Ointment: Apply to affected area 3 times daily; re-evaluate after 3 to 5 days if no clinical response</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Secondary skin infections:</b> Topical: Cream: Apply to affected area 3 times daily for 10 days; re-evaluate after 3 to 5 days if no clinical response</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Elimination of MRSA colonization:</b> Intranasal: Approximately one-half of the ointment from the single-use tube should be applied into one nostril and the other half into the other nostril twice daily (morning and evening) for 5 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Surgical prophylaxis in methicillin-resistant <i>S. aureus</i> (MRSA) carriers (off-label use): </b>Intranasal: Approximately one-half of the ointment from the single-use tube should be applied into one nostril and the other half into the other nostril twice daily for 5 days (Bode, 2010; Lee, 2013)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198538\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=mupirocin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Mupirocin: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Eradication of nasal MRSA:</b> Intranasal: Children &ge;12 years and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Impetigo:</b> Topical: Ointment: Infants &ge;2 months, Children, and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Secondary skin infections:</b> Topical: Cream: Infants &ge;3 months, Children, and Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198522\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24794643\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24794644\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198500\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cream, External, as calcium [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Bactroban: 2% (15 g, 30 g)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2% (15 g, 30 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, External: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Centany AT: 2% [contains propylene glycol monostearate]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ointment, External: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Bactroban: 2% (22 g [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Centany: 2% (30 g) [contains propylene glycol monostearate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2% (15 g, 22 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ointment, Nasal, as calcium [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Bactroban Nasal: 2% (1 g)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198487\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F803172\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intranasal ointment: After application into nostrils, press sides of nose together and gently massage to spread ointment throughout the insides of the nostrils for ~1 minute. Packaged in single-use tubes; discard after use; do not re-use. Not for use in eyes. In case of accidental contact in or near eyes, rinse well with water. Do not apply concurrently with any other intranasal products. Wash hands before and after application.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topical cream, ointment: For external use only; not for use in eyes or on mucous membranes (components may be absorbed systemically and cause drying and irritation). Apply small amount to affected area using gauze pad or cotton swab; area may be covered with a gauze dressing if desired. In case of accidental contact in or near eyes, rinse well with water. Wash hands before and after application.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198501\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Topical infection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intranasal: Eradication of nasal colonization with methicillin-resistant <i>S. aureus</i> (MRSA) in adult and pediatric patients &ge;12 years of age and health care workers as part of a comprehensive infection control program to reduce the risk of infection among patients at high risk of MRSA infection during institutional outbreaks of infections with this microorganism</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitations of use: Insufficient data for use as part of an intervention program to prevent autoinfection of high-risk patients from their own <i>S. aureus</i> nasal colonization or for general prophylaxis of any infection in any patient population.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topical cream: Treatment of secondary infected traumatic skin lesions (up to 10 cm in length or 100 cm<sup>2</sup> in area) due to susceptible isolates of <i>S. aureus</i> and <i>S. pyogenes</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topical ointment: Treatment of impetigo due to <i>S. aureus</i> and <i>S. pyogenes</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25469178\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Surgical prophylaxis in methicillin-resistant S. aureus (MRSA) carriers (intranasal administration)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198564\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Bactroban may be confused with bacitracin, baclofen, Bactrim</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198494\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Headache (2% to 9%), localized burning (&lt;4%), stinging sensation (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Pruritus (&le;2%), skin rash (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Nausea (1% to 5%), dysgeusia (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Local: Local pain (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Rhinitis (6%), respiratory congestion (5%), pharyngitis (4%), cough (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Abdominal pain, aphthous stomatitis, blepharitis, cellulitis, <i>Clostridium difficile</i> associated diarrhea, contact dermatitis, dermatitis, diarrhea, dizziness, epistaxis, erythema, hypersensitivity reaction, increased wound secretion, localized edema, localized tenderness, otalgia, urticaria, wound infection (secondary), xeroderma, xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198504\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to mupirocin or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198491\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: May be associated with systemic allergic reactions, including anaphylaxis, urticarial, angioedema, and generalized rash. If a systemic reaction occurs, discontinue use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Irritation: If sensitization or local irritation occurs, discontinue use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Topical ointment and intranasal: Use with caution in patients with renal impairment (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&quot;gasping syndrome&quot;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polyethylene glycol: Potentially toxic amounts of polyethylene glycol contained in some topical products may be absorbed percutaneously in patients with extensive burns or open wounds. Do not use polyethylene glycol-based ointments in conditions where absorption of large quantities of polyethylene glycol is possible, especially in the presence of moderate or severe renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: For external use only. Avoid contact with eyes; in case of accidental contact in or near eyes, rinse well with water.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Intranasal: May cause severe burning and tearing in eyes (resolves within days to weeks after discontinuation). Available in single-use tubes to decrease risk of contamination.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Topical cream and ointment: Not for ophthalmic or nasal use or use on mucosal surfaces. May cover treated areas with gauze dressing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Limitations of use:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Nasal ointment: There are insufficient data to establish that product is safe and effective as part of an intervention program to prevent autoinfection of high-risk patients from their own nasal colonization with <i>S. aureus</i>; should not be used for general prophylaxis of any infection in any patient population; &gt;90% of patients had eradication of nasal colonization within 2 to 4 days after therapy was completed; ~30% recolonization within 4 weeks of therapy was reported in one study.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Topical ointment: Should not be used with intravenous (IV) cannulae or at central IV sites because of the potential to promote fungal infections and antimicrobial resistance.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299730\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198495\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9668&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198508\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Systemic absorption following topical application is minimal.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20616365\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if mupirocin is present in breast milk. Systemic absorption following topical application is minimal, and significant exposure to a breastfeeding infant is not expected. If treatment to the breast and/or nipple is needed, the area should be thoroughly washed prior to breastfeeding to limit potential exposure to the infant. According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198490\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Binds to bacterial isoleucyl transfer-RNA synthetase resulting in the inhibition of protein synthesis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198503\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Topical ointment and cream: Penetrates outer layers of skin; systemic absorption minimal through intact skin</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Intranasal: Adults: ~3%; Neonates and premature infants: Absorption may be significant</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: &gt;97%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Rapidly metabolized to monic acid (inactive)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life: 17 to 36 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (as monic acid [inactive])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198507\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Bactroban External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2% (15 g): $124.93</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Mupirocin Calcium External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2% (15 g): $245.16</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Centany AT External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2% (1): $306.38</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Ointment</b> (Bactroban Nasal Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2% (1 g): $20.49</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Ointment</b> (Centany External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2% (30 g): $306.38</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Ointment</b> (Mupirocin External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2% (22 g): $38.70</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198509\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Bacidal (TH);</li>\n      <li>Bacron (BD);</li>\n      <li>Bactafect (TH);</li>\n      <li>Bactermin (TW);</li>\n      <li>Bactex (TH);</li>\n      <li>Bactifree (PH);</li>\n      <li>Bactocin (BR, PH);</li>\n      <li>Bactoderm (ID, IL);</li>\n      <li>Bactokil (TH);</li>\n      <li>Bactokill (BD);</li>\n      <li>Bactreat (PH);</li>\n      <li>Bactrobaan (DE);</li>\n      <li>Bactroban (AE, AR, AT, AU, BB, BD, BE, BF, BG, BH, BJ, BM, BR, BS, BZ, CH, CI, CL, CN, CY, CZ, DK, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, GY, HK, HU, ID, IE, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KR, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, MX, MY, NE, NG, NL, NO, NZ, OM, PH, PK, PL, PR, PT, PY, QA, RU, SA, SC, SD, SE, SG, SI, SK, SL, SN, SR, SY, TH, TN, TR, TT, TW, TZ, UA, UG, UY, VE, VN, YE, ZA, ZM, ZW);</li>\n      <li>Bactroban Nasal Ointment (AU);</li>\n      <li>Bactrocin (LK);</li>\n      <li>Banbact (TH);</li>\n      <li>Bantix (CN, PY);</li>\n      <li>Betrion (HR);</li>\n      <li>Dermasafe (TW);</li>\n      <li>Dermatech Bantix (CO);</li>\n      <li>Dermucor S (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Esroban (KR);</li>\n      <li>Foskina (PH);</li>\n      <li>Mertus (ID);</li>\n      <li>Mupiban (LK);</li>\n      <li>Mupicin (PH);</li>\n      <li>Mupider (NZ, SG);</li>\n      <li>Mupiderm (FR);</li>\n      <li>Mupiral (EC);</li>\n      <li>Mupiroban (KR);</li>\n      <li>MupiroNasal (BG);</li>\n      <li>Mupirox (AR, PE);</li>\n      <li>Mupirox Nasal (AR);</li>\n      <li>Muporin (TH);</li>\n      <li>Muprin (HK, ID, LK, MY, PH);</li>\n      <li>Muropa (HK);</li>\n      <li>Murozin (MY);</li>\n      <li>Pibaksin (ID, LK);</li>\n      <li>Plasimmine (ES);</li>\n      <li>Sinpebac (MX);</li>\n      <li>Spectroderm (PE);</li>\n      <li>Supirocin (MY, SG, TH, ZW);</li>\n      <li>Systop (BD);</li>\n      <li>Tapocin (BD);</li>\n      <li>Turixin (DE);</li>\n      <li>Vidox (UY)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mupirocin-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bactroban (mupirocin) cream [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bactroban Nasal (mupirocin) ointment [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bactroban (mupirocin) ointment [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blumer JL, Lemon E, O'Horo J, et al. Changing Therapy for Skin and Soft Tissue Infections in Children: Have We Come Full Circle? <i>Pediatr Infect Dis J</i>. 1987;6(1):117-122.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mupirocin-drug-information/abstract-text/3547287/pubmed\" target=\"_blank\" id=\"3547287\">3547287</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20054045\"></a>Bode LG, Kluytmans JA, Wertheim HF, et al. Preventing surgical-site infections in nasal carriers of <i>Staphylococcus aureus</i>. <i>N Engl J Med</i>. 2010;362(1):9-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mupirocin-drug-information/abstract-text/20054045/pubmed\" target=\"_blank\" id=\"20054045\">20054045</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Britton JW, Fajardo JE, Krafte-Jacobs B. Comparison of Mupirocin and Erythromycin in the Treatment of Impetigo. <i>J Pediatr</i>. 1990;117(5):827-829.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mupirocin-drug-information/abstract-text/2121951/pubmed\" target=\"_blank\" id=\"2121951\">2121951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centany ointment (mupirocin calcium) [prescribing information]. Allegan, MI: Medimetriks Pharmaceuticals Inc; June 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mupirocin-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goldfarb J, Crenshaw D, O'Horo J, et al. Randomized Clinical Trial of Topical Mupirocin Versus Oral Erythromycin for Impetigo. <i>Antimicrob Agents Chemother</i>. 1988;32(12):1780-1783.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mupirocin-drug-information/abstract-text/3149884/pubmed\" target=\"_blank\" id=\"3149884\">3149884</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mupirocin-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24056477\"></a>Lee AS, Cooper BS, Malhotra-Kumar S, et al; MOSAR WP4 Study Group. Comparison of strategies to reduce methicillin-resistant <i>Staphylococcus aureus</i> rates in surgical patients: a controlled multicenter intervention trial. <i>BMJ Open</i>. 2013:3:e003126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mupirocin-drug-information/abstract-text/24056477/pubmed\" target=\"_blank\" id=\"24056477\">24056477</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perl TM, Cullen JJ, Wenzel RP, et al. Intranasal Mupirocin to Prevent Postoperative <i>Staphylococcus aureus</i> Infections. <i>N Engl J Med</i>. 2002;346(24):1871-1877.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mupirocin-drug-information/abstract-text/12063371/pubmed\" target=\"_blank\" id=\"12063371\">12063371</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9668 Version 161.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F198518\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F198519\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F198557\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F198521\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F198538\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F198522\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F24794643\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F24794644\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F198500\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F198487\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F803172\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F198501\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25469178\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F198564\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F198494\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F198504\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F198491\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299730\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F198495\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F198508\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20616365\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F198490\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F198503\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F198507\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F198509\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9668|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=mupirocin-patient-drug-information\" class=\"drug drug_patient\">Mupirocin: Patient drug information</a></li><li><a href=\"topic.htm?path=mupirocin-pediatric-drug-information\" class=\"drug drug_pediatric\">Mupirocin: Pediatric drug information</a></li></ul></div></div>","javascript":null}